ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: psoriasis

Multispecialty Team Approach Key to Diagnosing, Treating Neutrophilic Dermatosis

Thomas R. Collins  |  February 15, 2017

WASHINGTON, D.C.—Often, no clear explanation exists in neutrophilic dermatosis cases that links a patient’s skin disorder with an internal condition, expert Joseph Jorizzo, MD, professor, founder and former chair of the Dermatology Department at Wake Forest University in Winston-Salem, N.C., and professor of clinical dermatology at Wevascularill Cornell Medical College in New York, told attendees…

Filed under:ConditionsMeeting Reports Tagged with:2016 ACR/ARHP Annual MeetingArthritisBehçet’s diseaseboweldermatosisDiagnosisneutrophilic vascular reactionsreactive diseaserheumatologistrheumatologySweet's syndromeTreatment

When Symptoms of Rheumatic Disorder Point to Endocrine Disease

Thomas R. Collins  |  February 15, 2017

WASHINGTON, D.C.—“Rheumatic manifestations are [often] the initial presentation of a systemic disease, but they can [also] occur during the course of the disorder,” said Joseph Markenson, MD, speaking in the ACR/ARHP Annual Meeting talk, Rheumatic Manifestations of Endocrine Disease, during the ACR Review Course. Dr. Markenson is professor of clinical medicine and a rheumatologist at Weill…

Filed under:ConditionsMeeting Reports Tagged with:2016 ACR/ARHP Annual MeetingdiabetesDiagnosisendocrine diseasehypothyroid myopathyhypothyroidismmanifestationRheumatic DiseaserheumatologistrheumatologysymptomtherapyTreatment

Monkey Business Images/shutterstock.com

Medical Paradoxes in Clinic, Lab Should Encourage Physicians to Reappraise Ideas about Health and Disease

Simon M. Helfgott, MD  |  January 19, 2017

Wash your hands. This most basic tenet of proper hygiene has been drummed into our heads for years. It’s an obvious infection prevention activity, yet for years, compliance among physicians and other caregivers has been lackluster. To rectify this matter, regulatory agencies began auditing hospital staff adherence to this axiom of infection prevention. Not only…

Filed under:OpinionResearch RheumRheuminationsSpeak Out Rheum Tagged with:clinicDietDiseaseDrugslaboutcomeparadoxpatient careResearchrheumatologistrheumatologySmoking

Rheumatology Drug Updates: Giant Cell Arteritis Relapse Possible if Tocilizumab Discontinued; Plus Updates on Rituximab, Etanercept

Michele B. Kaufman, PharmD, BCGP  |  January 19, 2017

GCA Relapse Possible When Discontinuing Tocilizumab In a Phase 2 randomized, controlled trial, tocilizumab, an anti-IL-6 biologic agent, was shown to induce and maintain remission for up to 52 weeks in patients with giant cell arteritis (GCA).1 During this trial, patients with GCA were randomized in a 2:1 ratio to receive 8 mg/kg bodyweight tocilizumab…

Filed under:Drug UpdatesResearch Rheum Tagged with:ApprovalsdrugetanerceptFDAGiant Cell Arteritisoutcomepatient careQualityrelapseResearchrheumatologyrituximabSafetytrial

Psoriatic Arthritis Linked to Increased Heart Disease Risk

Carolyn Crist  |  January 17, 2017

(Reuters Health)—Arthritis that accompanies the skin condition psoriasis may also come with a higher risk of heart problems, according to a Hong Kong study. In particular, patients with psoriatic arthritis may have a three- to four-fold higher prevalence of coronary atherosclerosis. Clinicians need to identify patients with high cardiovascular (CV) risk so they can provide…

Filed under:ConditionsPsoriatic Arthritis Tagged with:coronary plaqueHeart DiseaseNational Psoriasis FoundationPsoriasispsoriatic arthritis

Step Therapy, Biosimilars among ACR’s 2017 State-Level Priorities

Kelly Tyrrell  |  January 17, 2017

Opportunities and challenges will continue to face the rheumatology community in 2017. In response to these challenges, the ACR has outlined its federal– and state-level legislative and regulatory healthcare priorities for the year. Howard Blumstein, MD, chair of the ACR Affiliate Society Council, says that achieving at least some of these priorities at the state…

Filed under:Legislation & AdvocacyProfessional Topics Tagged with:Biosimilarsprior authorizationspecialty tieringstep therapy

Guselkumab Improves Active Psoriatic Arthritis

Michele B. Kaufman, PharmD, BCGP, & Lara C. Pullen, PhD  |  January 11, 2017

A study showed that guselkumab may decrease symptoms of psoriatic arthritis and improve quality of life in adult patients…

Filed under:Biologics/DMARDsDrug Updates

The OPAL Beyond Study: Tofacitinib Phase 3 Results Positive for Treating PsA

Michele B. Kaufman, PharmD, BCGP  |  December 20, 2016

In a recent study, patients with psoriatic arthritis taking tofacitinib had a decrease in disease activity compared with placebo…

Filed under:ConditionsDrug UpdatesPsoriatic Arthritis Tagged with:Disease-modifying antirheumatic drugs (DMARDs)Janus Kinase Inhibitorspsoriatic arthritisTofacitinib

Obesity & Rheumatic Disease

Richard Quinn  |  December 9, 2016

“Obesity is an inflammatory state, so it is in the landscape of the rheumatologist,” says Christopher Ritchlin, MD, MPH. And the more attention rheumatologists pay to obesity, the better…

Filed under:Conditions Tagged with:DietinflammationObesitypreventiveRheumatic Disease

FDA Update on Rituximab & Etanercept; Plus New ACP Gout Guideline

Michele B. Kaufman, PharmD, BCGP  |  November 30, 2016

The FDA is considering an application for subcutaneous rituximab and has approved an application for etanercept to treat pediatric patients with plaque psoriasis…

Filed under:Biologics/DMARDsConditionsDrug UpdatesGout and Crystalline ArthritisPediatric Conditions Tagged with:American College of PhysiciansetanerceptFDAFood and Drug AdministrationGoutguidelinePediatricplaque psoriasisrituximab

  • « Previous Page
  • 1
  • …
  • 36
  • 37
  • 38
  • 39
  • 40
  • …
  • 56
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2025 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences